Pharmaceutical

EHA 2025: AstraZeneca’s surovatamig is potential next-gen BiTE for R/R B-ALL

EHA 2025: Surovatamig shows promise, but needs to outperform established therapies such as Blincyto and Aucatzyl.

Jun 17, 2025 - 06:00
EHA 2025: AstraZeneca’s surovatamig is potential next-gen BiTE for R/R B-ALL
EHA 2025: Surovatamig shows promise, but needs to outperform established therapies such as Blincyto and Aucatzyl.
Read the original article

Tags:

Previous Article

FDA approves MSD’s Keytruda to treat head and neck cancer

Next Article

Sarepta and Roche halt DMD gene therapy’s use after second death  

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Untangling the Complexities of Cell and Gene Therapy Clinical Trials: A Supply Chain Perspective 

Untangling the Complexities of Cell and Gene Therapy Cl...

May 24, 2023

STAT+: A Q&A with Vertex founder Joshua Boger on Casgevy, the biotech industry, and Elon Musk

STAT+: A Q&A with Vertex founder Joshua Boger on Casgev...

Dec 11, 2023

Eton acquires US rights to neonatal diabetes treatment from AMMTeK

Eton acquires US rights to neonatal diabetes treatment ...

Nov 27, 2024